Botulinum toxin (BT), one of the most powerful inhibitors that prevents the release of acetylcholine from nerve endings, represents an alternative therapeutic approach for “spastic” disorders of the gastrointestinal tract such as achalasia, gastroparesis, sphincter of Oddi dysfunction, chronic anal fissures, and pelvic floor dyssynergia. BT has proven to be safe and this allows it to be a valid alternative in patients at high risk of invasive procedures but long-term efficacy in many disorders has not been observed, primarily due to its relatively short duration of action. Administration of BT has a low rate of adverse reactions and complications. However, not all patients respond to BT therapy, and large randomized controlled trials are lacking for many conditions commonly treated with BT. The local injection of BT in some conditions becomes a useful tool to decide to switch to more invasive therapies. Since 1980, the toxin has rapidly transformed from lethal poison to a safe therapeutic agent, with a significant impact on the quality of life.

Cariati, M., Chiarello, M. M., Cannistra', M., Lerose, M. A., Brisinda, G., Gastrointestinal Uses of Botulinum Toxin, in S. M. Whitcup, M. H. (. (ed.), Botulinum toxin therapy, Springer Science and Business Media Deutschland GmbH, Geneve 2021: 263 185- 226. 10.1007/164_2019_326 [http://hdl.handle.net/10807/207597]

Gastrointestinal Uses of Botulinum Toxin

Brisinda, G.
Ultimo
Writing – Original Draft Preparation
2021

Abstract

Botulinum toxin (BT), one of the most powerful inhibitors that prevents the release of acetylcholine from nerve endings, represents an alternative therapeutic approach for “spastic” disorders of the gastrointestinal tract such as achalasia, gastroparesis, sphincter of Oddi dysfunction, chronic anal fissures, and pelvic floor dyssynergia. BT has proven to be safe and this allows it to be a valid alternative in patients at high risk of invasive procedures but long-term efficacy in many disorders has not been observed, primarily due to its relatively short duration of action. Administration of BT has a low rate of adverse reactions and complications. However, not all patients respond to BT therapy, and large randomized controlled trials are lacking for many conditions commonly treated with BT. The local injection of BT in some conditions becomes a useful tool to decide to switch to more invasive therapies. Since 1980, the toxin has rapidly transformed from lethal poison to a safe therapeutic agent, with a significant impact on the quality of life.
Inglese
Botulinum toxin therapy
978-3-030-66305-6
Springer Science and Business Media Deutschland GmbH
263
Cariati, M., Chiarello, M. M., Cannistra', M., Lerose, M. A., Brisinda, G., Gastrointestinal Uses of Botulinum Toxin, in S. M. Whitcup, M. H. (. (ed.), Botulinum toxin therapy, Springer Science and Business Media Deutschland GmbH, Geneve 2021: 263 185- 226. 10.1007/164_2019_326 [http://hdl.handle.net/10807/207597]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/207597
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact